|
GB9723780D0
(en)
*
|
1997-11-12 |
1998-01-07 |
Univ Manchester |
Regulation of ocular angiogenesis
|
|
CA2348835A1
(en)
|
1998-10-28 |
2000-05-04 |
Cornell Research Foundation, Inc. |
Methods for regulating angiogenesis and vascular integrity using trk receptor ligands
|
|
US7393823B1
(en)
|
1999-01-20 |
2008-07-01 |
Oregon Health And Science University |
HER-2 binding antagonists
|
|
US7396810B1
(en)
*
|
2000-08-14 |
2008-07-08 |
Oregon Health Sciences University |
Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
|
|
US7625859B1
(en)
|
2000-02-16 |
2009-12-01 |
Oregon Health & Science University |
HER-2 binding antagonists
|
|
AU3755900A
(en)
*
|
1999-03-15 |
2000-10-04 |
Chiron Corporation |
Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
|
|
US6943153B1
(en)
|
1999-03-15 |
2005-09-13 |
The Regents Of The University Of California |
Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
|
|
US7070959B1
(en)
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
US7303746B2
(en)
|
1999-06-08 |
2007-12-04 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating eye disorders with modified chimeric polypeptides
|
|
US6833349B2
(en)
*
|
1999-06-08 |
2004-12-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating inflammatory skin diseases
|
|
US7306799B2
(en)
|
1999-06-08 |
2007-12-11 |
Regeneron Pharmaceuticals, Inc. |
Use of VEGF inhibitors for treatment of eye disorders
|
|
US7653769B2
(en)
*
|
2006-12-14 |
2010-01-26 |
International Business Machines Corporation |
Management of devices connected to infiniband ports
|
|
US6821775B1
(en)
*
|
2000-02-11 |
2004-11-23 |
Genvec, Inc. |
Viral vector encoding pigment epithelium-derived factor
|
|
AUPQ592100A0
(en)
*
|
2000-02-29 |
2000-03-23 |
Council Of The Queensland Institute Of Medical Research, The |
A method of treatment and prophylaxis
|
|
HUP0300810A2
(hu)
|
2000-07-20 |
2003-08-28 |
M.G.V.S. Ltd. |
Mesterséges értranszplantátum, valamint ennek létrehozása és alkalmazása
|
|
US7175658B1
(en)
|
2000-07-20 |
2007-02-13 |
Multi-Gene Vascular Systems Ltd. |
Artificial vascular grafts, their construction and use
|
|
WO2002024234A2
(en)
*
|
2000-09-20 |
2002-03-28 |
The Regents Of The University Of California |
Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
|
|
GB0109781D0
(en)
*
|
2001-04-20 |
2001-06-13 |
Oxford Biomedica Ltd |
Vector system
|
|
WO2003062788A2
(en)
*
|
2002-01-17 |
2003-07-31 |
Genetix Pharamaceuticals, Inc. |
Method for inhibiting angiogenesis
|
|
AU2003215163A1
(en)
*
|
2002-02-12 |
2003-09-04 |
Vanderbilt University |
Inhibition of vegf receptor signaling reverses tumor resistance to radiotherapy
|
|
US20060234969A1
(en)
*
|
2003-03-07 |
2006-10-19 |
Anges Mg, Inc. |
Compositions and methods for inhibiting inflammation of vessel walls and formation of neointimal hyperplasia
|
|
JP2007528355A
(ja)
*
|
2003-03-07 |
2007-10-11 |
アンジェスＭｇ株式会社 |
血管壁の炎症および新生内膜過形成を阻害する組成物および方法
|
|
US20050239088A1
(en)
*
|
2003-05-16 |
2005-10-27 |
Shepard H M |
Intron fusion proteins, and methods of identifying and using same
|
|
PT1638591E
(pt)
|
2003-05-29 |
2013-05-22 |
Univ Manchester |
Agonistas de slrp de classe iii para a redução da formação de vasos sanguíneos
|
|
US7186699B2
(en)
|
2003-06-03 |
2007-03-06 |
Cell Genesys, Inc. |
Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
|
|
US7399612B2
(en)
|
2003-06-30 |
2008-07-15 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
NZ592039A
(en)
|
2003-08-27 |
2013-03-28 |
Ophthotech Corp |
Combination therapy for the treatment of ocular neovascular disorders
|
|
WO2005087808A2
(en)
|
2004-03-05 |
2005-09-22 |
Ludwig Institute For Cancer Research |
Growth factor binding constructs materials and methods
|
|
JP2008506366A
(ja)
*
|
2004-05-14 |
2008-03-06 |
レセプター バイオロジックス インコーポレイテッド |
細胞表面受容体アイソフォームならびにその同定および使用方法
|
|
US20070224194A1
(en)
*
|
2004-05-20 |
2007-09-27 |
Ludwig Institute For Cancer Research |
Methods for Inhibiting Angiogenesis and/or Lymphangiogenesis
|
|
CA2576030A1
(en)
*
|
2004-08-09 |
2006-02-23 |
Alios Biopharma Inc. |
Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
|
|
US7597884B2
(en)
*
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
|
US20060047153A1
(en)
*
|
2004-09-02 |
2006-03-02 |
Wonders Alan G |
Optimized liquid-phase oxidation
|
|
US7692036B2
(en)
|
2004-11-29 |
2010-04-06 |
Eastman Chemical Company |
Optimized liquid-phase oxidation
|
|
US7741515B2
(en)
*
|
2004-09-02 |
2010-06-22 |
Eastman Chemical Company |
Optimized liquid-phase oxidation
|
|
US7589231B2
(en)
*
|
2004-09-02 |
2009-09-15 |
Eastman Chemical Company |
Optimized liquid-phase oxidation
|
|
US7683210B2
(en)
*
|
2004-09-02 |
2010-03-23 |
Eastman Chemical Company |
Optimized liquid-phase oxidation
|
|
US7381836B2
(en)
*
|
2004-09-02 |
2008-06-03 |
Eastman Chemical Company |
Optimized liquid-phase oxidation
|
|
US7482482B2
(en)
|
2004-09-02 |
2009-01-27 |
Eastman Chemical Company |
Optimized liquid-phase oxidation
|
|
US7399882B2
(en)
*
|
2004-09-02 |
2008-07-15 |
Eastman Chemical Company |
Optimized liquid-phase oxidation
|
|
US7586000B2
(en)
*
|
2004-09-02 |
2009-09-08 |
Eastman Chemical Company |
Optimized liquid-phase oxidation
|
|
US7361784B2
(en)
*
|
2004-09-02 |
2008-04-22 |
Eastman Chemical Company |
Optimized liquid-phase oxidation
|
|
US7608733B2
(en)
*
|
2004-09-02 |
2009-10-27 |
Eastman Chemical Company |
Optimized liquid-phase oxidation
|
|
US7504535B2
(en)
*
|
2004-09-02 |
2009-03-17 |
Eastman Chemical Company |
Optimized liquid-phase oxidation
|
|
US7910769B2
(en)
*
|
2004-09-02 |
2011-03-22 |
Eastman Chemical Company |
Optimized liquid-phase oxidation
|
|
US7371894B2
(en)
*
|
2004-09-02 |
2008-05-13 |
Eastman Chemical Company |
Optimized liquid-phase oxidation
|
|
US7608732B2
(en)
*
|
2005-03-08 |
2009-10-27 |
Eastman Chemical Company |
Optimized liquid-phase oxidation
|
|
US7495125B2
(en)
*
|
2004-09-02 |
2009-02-24 |
Eastman Chemical Company |
Optimized liquid-phase oxidation
|
|
US7582793B2
(en)
*
|
2004-09-02 |
2009-09-01 |
Eastman Chemical Company |
Optimized liquid-phase oxidation
|
|
US7692037B2
(en)
*
|
2004-09-02 |
2010-04-06 |
Eastman Chemical Company |
Optimized liquid-phase oxidation
|
|
US7568361B2
(en)
*
|
2004-09-02 |
2009-08-04 |
Eastman Chemical Company |
Optimized liquid-phase oxidation
|
|
US7507857B2
(en)
*
|
2004-09-02 |
2009-03-24 |
Eastman Chemical Company |
Optimized liquid-phase oxidation
|
|
US7390921B2
(en)
*
|
2004-09-02 |
2008-06-24 |
Eastman Chemical Company |
Optimized liquid-phase oxidation
|
|
US7563926B2
(en)
*
|
2004-09-02 |
2009-07-21 |
Eastman Chemical Company |
Optimized liquid-phase oxidation
|
|
DK2229956T3
(da)
|
2004-09-13 |
2013-07-29 |
Genzyme Corp |
Multimere konstruktioner
|
|
WO2006042002A2
(en)
*
|
2004-10-05 |
2006-04-20 |
Oregon Health And Science University |
Compositions and methods for treating disease
|
|
US20090087424A1
(en)
*
|
2004-11-26 |
2009-04-02 |
Noriko Miyamoto |
Modulating Retinal Pigmented Epithelium Permeaion By Inhibiting Or Activating VEGFR-1
|
|
US20060116531A1
(en)
*
|
2004-11-29 |
2006-06-01 |
Wonders Alan G |
Modeling of liquid-phase oxidation
|
|
US8211864B2
(en)
*
|
2005-01-26 |
2012-07-03 |
Medical College Of Georgia Research Institute |
Compositions and methods for the intracellular disruption of VEGF and VEGFR-2 by intraceptors
|
|
US7303748B2
(en)
|
2005-02-02 |
2007-12-04 |
Regeneron Pharmaceuticals, Inc. |
Method of treating eye injury with local administration of a VEGF inhibitor
|
|
EP2447281B1
(en)
|
2005-03-24 |
2015-12-16 |
ThromboGenics N.V. |
Novel anti-PLGF antibody
|
|
US20090170769A1
(en)
*
|
2005-05-13 |
2009-07-02 |
Pei Jin |
Cell surface receptor isoforms and methods of identifying and using the same
|
|
US7884232B2
(en)
*
|
2005-06-16 |
2011-02-08 |
Eastman Chemical Company |
Optimized liquid-phase oxidation
|
|
EP1904095B1
(en)
|
2005-06-30 |
2013-05-29 |
VIB, vzw |
Treatment of liver cirrhosis and its complications
|
|
KR100737286B1
(ko)
|
2005-08-31 |
2007-07-13 |
박기랑 |
ＶＥＧＦＲ 트렁케이티드 ｃＤＮＡ를 함유하는 재조합아데노-연관 바이러스 및 이를 함유하는 암-특이적 유전자치료제
|
|
US7355068B2
(en)
|
2006-01-04 |
2008-04-08 |
Eastman Chemical Company |
Oxidation system with internal secondary reactor
|
|
US7358389B2
(en)
*
|
2006-01-04 |
2008-04-15 |
Eastman Chemical Company |
Oxidation system employing internal structure for enhanced hydrodynamics
|
|
US9073997B2
(en)
*
|
2007-02-02 |
2015-07-07 |
Vegenics Pty Limited |
Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis
|
|
US7871100B2
(en)
*
|
2007-03-27 |
2011-01-18 |
Wonderland Nurserygoods Co., Ltd. |
Collapsible stroller
|
|
US20080260820A1
(en)
*
|
2007-04-19 |
2008-10-23 |
Gilles Borrelly |
Oral dosage formulations of protease-resistant polypeptides
|
|
CA2736929C
(en)
|
2008-10-02 |
2019-02-26 |
Life Sciences Research Partners Vzw |
Inhibition of plgf to treat philadelphia chromosome positive leukemia
|
|
KR101248912B1
(ko)
*
|
2009-12-31 |
2013-03-29 |
한양대학교 산학협력단 |
항혈관신생 활성을 가지는 재조합 아데노바이러스
|
|
PL2601214T3
(pl)
|
2010-08-06 |
2018-05-30 |
Genzyme Corporation |
Kompozycje antagonistyczne wobec VEGF oraz ich zastosowania
|
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
|
ES2628321T3
(es)
|
2011-12-01 |
2017-08-02 |
Thrombogenics N.V. |
Mejora del resultado de una trabeculectomía
|
|
TWI775096B
(zh)
|
2012-05-15 |
2022-08-21 |
澳大利亞商艾佛蘭屈澳洲私營有限公司 |
使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
|
|
PT2956476T
(pt)
|
2013-02-18 |
2020-02-21 |
Vegenics Pty Ltd |
Moléculas de ligação e usos destas
|
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
KR102537394B1
(ko)
|
2014-03-17 |
2023-05-30 |
애드베룸 바이오테크놀로지스, 인코포레이티드 |
원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
|
|
KR102486321B1
(ko)
|
2014-07-18 |
2023-01-09 |
사노피 |
암을 앓고 있는 것으로 의심되는 환자를 아플리베르셉트로 치료한 결과를 예측하는 방법
|
|
MY187898A
(en)
|
2015-03-02 |
2021-10-27 |
Adverum Biotechnologies Inc |
Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
|
|
GB2545763A
(en)
|
2015-12-23 |
2017-06-28 |
Adverum Biotechnologies Inc |
Mutant viral capsid libraries and related systems and methods
|
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
US20230372397A1
(en)
|
2020-10-06 |
2023-11-23 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|